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ABSTRACT 
Objective: Deregulation of FAS/FASL system may lead to immune escape and influence 
bacillus Calmette-Guérin (BCG) immunotherapy outcome, currently the gold standard adjuvant 
treatment for high-risk non-muscle invasive bladder tumors. Among other events, functional 
promoter polymorphisms of FAS and FASL genes may alter their transcriptional activity. 
Therefore we aim to evaluate the role of FAS and FASL polymorphisms in the context of BCG 
therapy, envisaging the validation of these biomarkers to predict response 
Patients and Methods: DNA extracted from peripheral blood from 125 bladder cancer 
patients treated with BCG therapy, was analyzed by Polymerase Chain Reaction (PCR) – 
Restriction Fragment Length Polymorphism for FAS-670A/G and FASL-844T/C polymorphisms. 
FASL mRNA expression was analyzed by real time PCR. 
Results: Carriers of FASL-844 CC genotype present a decrease recurrence free survival 
after BCG treatment, when compared to FASL-844 T allele carriers (mean 71.5 vs. 97.8 months, 
p=0.030) and have an increased risk of BCG treatment failure (HR=1.922; 95%CI: [1.064-3.471]; 
p=0.030). Multivariate analysis shows that FASL-844T/C and therapeutic scheme are 
independent predictive markers of recurrence after treatment. The evaluation of FASL gene 
mRNA levels demonstrated that patients carrying FASL-844 CC genotype had higher FASL 
expression in bladder tumors (p = 0.0027). Higher FASL levels were also associated with an 
increased risk of recurrence after BCG treatment (HR=2,833; 95%CI: [1.012-7.929]; p=0.047). 
FAS-670A/G polymorphism analysis did not reveal any association with BCG therapy outcome. 
Conclusions: Our results suggest that analysis of FASL-844T/C , but not FAS-670A/G 
polymorphisms, may be used as a predictive marker of response to BCG immunotherapy. 
 
 
Keywords: Bladder Cancer; BCG immunotherapy; Polymorphisms; Fas/FasL; 
predictive markers. 
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INTRODUCTION 
 
The Fas/Fas ligand (FasL) system is one of the major pathways of apoptosis and an 
important regulator of cell proliferation and immune system regulation. During carcinogenesis, 
tumor cells may alter this mechanisms to subvert the immune system and suppress the 
antitumor immune response [1].  
Fas/FasL further controls T cell apoptosis after immune reaction by the process of 
activation-induced cell death (AICD) [2]. This mechanism involves the overexpression of both 
Fas and FasL upon activation by antigen or other stimuli, subsequently proŵotiŶg Đell ͞suicide͟ 
or ͞fratricide͟ [3]. Decreased Fas and elevated FasL expression has been found in many types 
of cancer including bladder cancer [4]. It has been shown that tumor cells may counterattack 
Fas-sensitive tumor-infiltrating lymphocytes (TILs) using heightened expression of FasL. This 
mechanism is thought to lead to tumor cell immune escape, thus contributing to cancer 
formation and progression [5]. 
Functional polymorphisms in the promoter region of FAS and FASL genes have been 
identified and alter the transcriptional activity of these genes, which may have implications in 
the Fas/FasL pathways [6, 7].  Moreover, they have been associated with a higher risk in 
various cancer models [8, 9]. In bladder cancer, FASL-844 CC genotype was associated with a 
significantly increased risk of bladder cancer [10]. However, the role of Fas/FasL and its 
functional polymorphisms have not been addressed in the context of bladder cancer 
treatment. 
At the moment, the most effective treatment for high risk non-muscle invasive bladder 
cancer (NMIBC) consists of an immunotherapy with bacillus Calmette-Guérin (BCG) [11] . 
Generally it is performed as adjuvant to transurethral resection of bladder tumor (TURBT) in 
intermediate and high risk patients [11]. However, several studies demonstrated that 30% of 
the patients fail to respond to this therapeutic and in some cases the tumor may become more 
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aggressive [12]. Thus, early identification of patients better served by alternative and/or more 
aggressive approaches such as cystectomy is a critical aspect in the management of high-risk 
NMIBC [13, 14]. However, at the moment there are no established biomarkers to determine 
the outcome of BCG immunotherapy. Recently, several authors suggest that immunological 
predictive markers may yield promising clinical value in the context of predicting BCG 
immunotherapy outcome [14-16]. 
One of the main pathways of BCG anti-tumoral response is mediated by BCG and 
lymphokine-activated killer cells (BAK and LAK) [17]. Although it has been demonstrated that 
Fas/FasL pathway is not directly involved in BCG anti-tumoral effect [17, 18], BCG effector cells 
are sensitive to FasL-dependent AICD regulation [2] and possibly to FasL counterattack by 
tumor cells. Hypothesizing that a deregulation of Fas/FasL pathway may lead to immune 
escape and influence the efficacy of BCG immunotherapy, in this study we aimed to evaluate 
the role of FAS and FASL polymorphisms in the context of BCG therapy response. To the best of 
our knowledge, this is the first study addressing this subject and may provide important 
insights about the role of these molecules as predictive markers of BCG treatment outcome. 
 
MATERIAL AND METHODS 
 
Population 
In this retrospective case-control study, all intermediate and high-risk NMIBC patients 
who underwent transurethral resection followed by BCG therapy between 1998 and 2006 at 
the Portuguese Institute of Oncology – Porto were eligible for this study. From a total of 193 
patients, 14 had already died. The remaining 179 were invited to participate in the study, 70% 
of which accepted [19]. Patients blood samples were collected during 2006 and 2008 on 
patieŶt’s folloǁ-up consultation.  All patients received intravesical instillation of BCG for 6 
consecutive weeks starting 2-3 weeks after surgery, i.e., induction scheme (iBCG) and 56% 
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underwent further instillations every 3 months for two years, i.e., maintenance scheme 
(mBCG). The iBCG group includes patients treated before the European Association of Urology 
guidelines  recommending the mBCG scheme and patients showing significant intolerance to 
long BCG treatment. The mean diagnostic age of the patients was 61,54±10,63 (min:36; 
max:97) years, with a male:female sex ratio of 105:20. The patients were followed by 
cystoscopy and urinary cytology every 3 months for the first year, every 6 month for the 
second year and every 12 months thereafter. The median follow-up time was 60 months (from 
6 till 135 months). Tumor recurrence was defined as a newly found bladder tumor after the 
treatment, with at least one tumor-free cystoscopy between. The end point of the study was 
recurrence-free survival (RFS), defined as the period between the beginning of BCG treatment 
until the date of the most recent cystoscopy or recurrence date. Non-responders, as opposed 
to responders, were defined as patients submitted to BCG treatment that showed tumor 
recurrence. All clinicopathological information was obtained froŵ patieŶts’ ĐliŶiĐal reĐords. 
Informed and written consent from each patient was obtained. The institutional ethics 
committee approved the study. 
 
DNA extraction and genotyping 
Peripheral blood samples were collected following standard venipuncture technique in 
EDTA-containing tubes, and the DNA was extracted from the white blood cell fraction using a 
salting out protocol [20] and storage at -20ºC. 
The FAS and FASL genetic polymorphisms were genotyped using RFLP-PCR technique. 
The primers and enzymes used in FAS-670A/G and FASL-844T/C polymorphisms genotyping 
were the described by other authors [6, 7]. The PCR-RFLP conditions were the same as used by 
previously [20]. Genotyping data was read blind to the study endpoint. For quality control, 10% 
of the samples were randomly selected to a second PCR–RFLP analysis and 100% of 
concordance was observed.  
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RNA extraction and FASL mRNA expression analysis 
A total of 34 tumor samples were randomly selected from the initial population 
according to the patient genotype for FASL-844T/C polymorphism (17 TT/TC and 17 CC). RNA 
was isolated from formalin-fixed paraffin-embedded (FFPE) tissue samples using "Absolutely 
RNA® FFPE Kit" (Stratagene, La Jolla, CA). Up to 2μg of total RNA ǁas reǀerse transcribed with 
random primers, using the ͞High Capacity cDNA Reverse Transcription Kit͟ (Applied 
Biosystems, Foster City, CA). Real-time PCR amplification of cDNA samples was performed in a 
“tepOŶe™ Real-Time PCR System (Applied Biosystems) using TaqMan® Gene Expression 
Master Mix, primers and probes provided by Applied Biosystems. Expression of FASL was 
measured with TaqMan expression assay (ID: Hs00181225_m1) from Applied Biosystems . 
The raw -ΔCt was used to analyse the FASL expression in FASL-844 CC or TT/TC 
genotypes carriers and therefore used as an estimate of the mRNA relative levels. ΔCt staŶds 
for the difference between the cycle threshold (Ct) of the amplification curve of the target 
gene and that of the GAPDH. The efficiency of the amplification reaction for each primer-probe 
is above 95% (as determined by the manufacturer).  
 
Assessment of FasL expression by immunohistochemistry 
The same 34 FFPE tissue sections were screened for FasL by 
immunohistochemistry with the streptavidin/biotin peroxidase method using anti-FasL 
mouse monoclonal antibody clone 5D1 (Leica Biosystems, Wetzlar, Germany). Tissues 
were incubated with primary antibody overnight in a 1:35 dilution. A semi-quantitative 
approach was established to score the immunohistochemical labelling based on the 
percentage of cells that stained positively. The entire section was screened and the 
cases were classified as: Low FasL IHC expression when the percentage of positive cells 
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was above median value of the overall expression (<25%). When the overall expression 
was above 25%, it was classified as High FasL IHC expression. 
Statistical analysis 
Statistical data analysis was carried out using the computer software Statistical 
Package for Social Sciences—SPSS for Windows (version 15.0). Chi-square analysis was used to 
compare categorical variables. The odds ratio (OR) and its 95% confidence interval (CI) were 
calculated as a measurement of the association between genotypes and the risk of recurrence. 
Kaplan-Meier survival curves were used to evaluate correlation between genotypes and RFS 
and were compared by log-rank statistical test. Further, multiple Cox regression analysis was 
used to assess the effect of individual polymorphisms on the time to recurrence in BCG-treated 
patients and to adjust for potential confounders. Non parametric Mann-Whitney test was used 
to compare the differences in the mRNA expression between the study groups. 
 
RESULTS 
FAS and FASL polymorphisms as predictors of BCG immunotherapy outcome 
Regarding the evaluation of FAS-670A/G and FASL-844T/C polymorphisms, Table 1 
presents genotype frequencies and the risk of recurrence after BCG treatment. It was observed 
that FASL-844 CC genotype frequency is higher in patients with recurrence, when compared 
with responders group (37.5% vs. 24.7%). An increased risk was noticed (OR=1.8), although, 
not statistically significant.  
Kaplan-Meier function plots and probabilities analysis showed that FASL-844 CC 
genotype carriers have a shorter recurrence free survival after BCG treatment (mean 71.5 
months) when compared to T allele carriers (mean 97.8 months, p=0.030, Fig. 1). In order to 
estimate the risk associated to this difference, Cox regression was performed and it was found 
that  FASL-844 CC genotype carriers have an increase risk of BCG treatment failure (HR=1.897; 
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95%CI: [1.051-3.424]; p=0.034). Regarding FAS-670A/G polymorphism, no association was 
found with recurrence risk nor RFS.  
The relation between clinicopathological characteristics and response to BCG 
treatment (i.e., responders vs. non-responders) is presented in Table 2. It was observed that 
treatment scheme is associated with recurrence after treatment (35.1% vs. 58.3%, p=0.011). 
Our previous report, with the same sample dataset, showed that iBCG treated patients or 
patients with multiple tumors have a shorter RFS [19]. In the present study we performed 
univariate Cox Regression and found that patients treated only with iBCG scheme have 2-fold 
risk of recurrence after BCG immunotherapy (HR=2.096; 95%CI: [1.177-3.731]; p=0.012). 
However, the presence of multiple tumors revealed a trend to an increase risk of recurrence 
(HR=1.760; 95%CI: [0.981-3.159]; p=0.058). There are no association between the evaluated 
polymorphism and the clinicopathological characteristics. 
Therefore, multivariate Cox regression analysis adjusted to treatment scheme and 
multifocality was performed to assess the individual effect of FASL-844T/C on the risk of 
recurrence in BCG-treated patients. The results showed in table 3, reveal that independently of 
the treatment scheme adopted, patients carrying FASL-844 CC genotype as approximately a 2-
fold risk of early recurrence and that independently of the patient FASL-844 genotype, patients 
treated only with iBCG scheme have approximately 2.5-fold risk of early recurrence. Thus FASL-
844T/C, BCG scheme and multifocality are independent predictive factors of BCG 
immunotherapy outcome. 
 
FASL mRNA expression and its relation with FASL-844T/C and treatment response  
Of the 125 patients, 34 tumor tissues were available for evaluation of FASL mRNA 
expression levels. As shown in Fig. 2, significantly higher FASL mRNA levels were found in 
tumors from FASL-844 CC genotype patients than from TT or TC genotype patients (median 
mRNA relative levels,  -7.80 vs. -6.14±0.46, p = 0.0027). In our samples the normalizing gene 
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(GAPDH) presents stable Ct values (mean±standard deviation: 29.95±2.26), demonstrating that 
RNA recovered from FFPE is suitable for gene expression analysis.  
Individuals were categorized as high expressers (High FASL) when the normalized 
transcripts levels (mRNA relative levels) were above the geometric mean of all cases (> -7.04), 
while individuals with mRNA relative levels below -7.04 were categorized as low FASL 
expressers (Low FASL). From the High FASL group 78.6.% individuals were FASL-844 CC 
genotype carriers, whereas among Low FASL cases, only 30% were CC genotype (p=0.005). 
Kaplan-Meier analysis (Fig. 3) showed that High FASL individuals have a reduced RFS (mean 
51.4 months) when compared with Low FASL individuals (mean 96.2 months, p=0.030). 
Univariate Cox Regression analysis demonstrated that High FASL individuals have 
approximately 3-fold risk of recurrence after BCG treatment (HR=2.833; 95%CI: [1.012-7.929]; 
p=0.047). Immunohistochemistry was used to confirm FasL localization. It was observed that 
both FasL was present both in tumors and the immune infiltrates, independently of the FASL-
844T/C genotype. The FasL overall expression was in accordance with the levels of gene 
expression (p<0.001 – Fig. 4). No association was found between the FasL expression in the 
tumor and BCG response as well as other clinicopathological characteristics. 
 
DISCUSSION 
 
The management of high-risk NMIBC relies mostly on an adjuvant immunotherapy 
consisting on intravesical instillations with BCG, performed after transurothelial resection of 
the tumor [11]. BCG promotes a strong local immune response that results in tumor 
elimination [13, 21, 22]. In our most recent systematic review on this subject we point out 
several markers such as CD68, ezrin, HSP90, CD83, IL2 urinary levels related with BCG response 
[14]. Several functional polymorphisms in genes such as NRAMP1, hGPX1, XPA, ERCC2 and 6 as 
well as in genes involved in inflammatory pathways (IL8, TNFA, IL6, TGFB1, COX2, IFNG) [14]. 
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All these genetic markers have been identified based on a candidate gene approach using well 
established polymorphisms. Still, at the moment there are no reliable biomarkers to determine 
the outcome of this therapeutics, thereby permitting the early identification of patients better 
served by alternative therapeutics or cystectomy [14, 16]. It has been long thought that such 
biomarkers may be encountered among molecules/cells involved in the mediation of immune 
responses at the tumor site [14-16]. Among these putative immune-related biomarkers is the 
Fas/FasL pathway. Still, its involvement in BCG-mediated tumor cells elimination remains 
controversial since some authors demonstrated that BCG anti-tumoral effect is not mediated 
by Fas/FasL [17, 18] while others found higher levels of these molecules in T lymphocytes after 
treatment [23]. Nevertheless, this pathway is responsible for the regulation of cell apoptosis, 
namely T cell depletion by increasing AICD rates [2], therefore a deregulation of this pathway 
may compromise the immune response mediated by BCG immunotherapy and consequently 
contribute to modulate the therapeutics outcome. Tumor cells are known to modulate and 
evade Fas-mediated apoptosis, by simultaneously down regulating their own Fas expression 
and promoting the expression of FasL on their surface [5]. This protects tumor cells against 
FasL-induced apoptosis and, at the same time, promotes the apoptosis of activated T-cells 
eǆpressiŶg FasL, iŶ ǁhat has ďeeŶ Đalled as the FasL ͞ĐouŶterattaĐk͟ [5]. Functional 
polymorphisms in FAS and FASL genes may unbalance the expression of Fas/FasL by tumor 
cells and  contribute to the establishment of an immune suppressive environment that favours 
tumor proliferation [5]. The unbalanced expression of Fas/FasL was observed in several 
tumors, including bladder cancer [4]. Moreover, the presence of the FAS and FASL 
polymorphism was correlated with an increased risk of developing bladder tumors [10] and 
with an enhanced T cell apoptosis after immune reaction [24]. 
Given the putative involvement Fas/FasL pathway on the immune response, one may 
hypothesize that functional polymorphisms affecting expression levels of this molecules may 
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deregulate this pathway contributing to the failure of BCG therapeutics [15]. Therefore it may 
be used as a predictive biomarker of BCG immunotherapy outcome.  
Since the FASL-844T/C polymorphism was never evaluated in the context of BCG 
therapy, in this study we have evaluated these polymorphism in a dataset of Portuguese 
patients and found that those carrying FASL–844 CC genotype presented an increased risk of 
recurrence after treatment. In order to corroborate if FASL–844 CC genotype was associated 
with higher basal expression levels of FasL, we have also evaluated mRNA levels of FASL gene 
in tumor samples. This showed that patients carrying FASL-844 CC genotype had higher FASL 
expression in bladder tumors, as previously reported for others models [7, 24]. We have also 
demonstrated that higher FASL levels were associated with an increased risk of recurrence 
after BCG treatment. This suggests that patients carrying FASL-844 CC genotype have higher 
FASL expression in T-cells membrane or in tumors which may indeed compromise the 
efficiency of BCG treatment by balancing the immunological boost promoted by the bacillus. 
Our results suggest that this may not occur by an overexpression of FasL in tumors. More 
studies are needed to determine whether it may result from enhanced AICD in T-cells.  
Herein we opted to extract RNA from FFPE tissues. Although mRNA extracted from 
FFPE is partial degraded, is possible to use this in real time PCR to obtain accurate and specific 
gene expression using amplicons under 100bp [25]. Based on these observations we choose 
amplicons lower than 100bp. We also observed that GADPH expression was stable among our 
samples and that the mean Ct was around 30. According to several authors this is an indicator 
of mRNA quality and amplification efficiency [25, 26]. Based in these concepts we can say that 
our RNA samples were suitable for expression analysis.  
Regarding FAS-670A/G analysis, we could confirm that this polymorphism is not 
associated with BCG treatment outcome in the Portuguese population, as described for the 
Indian population [27], suggesting that FAS-670A/G may not influence the molecular 
mechanisms underlying this therapeutics.  
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Clinicopathological characteristics as predictors of BCG immunotherapy outcome has been 
long studied, although the findings are controversial [28]. Herein, we evaluated the predictive 
value of all clinicopathological characteristics and found that only patients treated with iBCG or 
with multiple tumors present a higher risk of failure, which is in accordance with previous 
findings [19, 29, 30]. However multivariate analysis showed that this did not influence the 
biomarker value of FASL-844T/C in the context of response to BCG immunotherapy. Still, the 
main limitation of this study was the low number of mBCG cases, thus  the analysis of a larger 
patient set only treated with mBCG scheme will be required toto evaluate more accurately the 
value of this polymorphism in the context of the currently  adopted therapeutic scheme. 
This is the first report addressing the potential role of FASL-844T/C polymorphism as a 
predictive marker of BCG immunotherapy response. Despite the limited number of samples, a 
significant association with the outcome of the therapeutics was observed. This highlights that 
FASL-844T/C polymorphism could be included in a biomarker panel to guide the management 
of high-risk bladder cancers.  
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Figure legends 
 
Figure 1 – Association between FASL-844T/C genotypes and recurrence-free survival (RFS) in 
the studied patients. Kaplan-Meier analysis to assess the effect and log-rank test (p=0.030); + 
censored FASL-844 TT/TC carriers; ♦ censored FASL-844 CC carriers.  
 
Figure 2 – Real -Time PCR analysis for FASL mRNA levels in bladder tumors comparing 
expression leveles in patients carrying FASL-844 TT or TC genotypes and CC genotypes. The Box 
plots represents in the horizontal bar the median value for mRNA in each group, the 25th and 
75th percentile have been represented by the boxes. The whiskers represent the maximum 
and minimum values of the data, respectively. Black dots represent outliers. To compare the 
transcript levels between groups, non-parametric Mann-Whitney Test was applied. (**) – p = 
0,0027. 
 
Figure 3 – Effect of FASL mRNA levels in recurrence-free survival (RFS). Kaplan-Meier analysis 
to evaluate the association between Low or High FASL mRNA levels and RFS in the studied 
patients. Comparison performed by log-rank test (p=0.030); + censored Low FASL mRNA levels 
samples; ♦ censored High FASL mRNA levels samples. 
 
Figure 4 – Immunohistochemistry (IHC) using anti-FasL antibody. Representative image of 
tumor (dark arrow) and immune infiltrate (white arrow) expressing FasL in specimens with low 
and high expression of FASL mRNA (400X). In cases with low FASL mRNA the FasL protein 
expression was lower and less intense (A). In cases with high FASL mRNA expression, FasL was 
markedly and diffusely expressed in both the tumor and the immune infiltrate (B). Expression 
of FASL mRNA is associated with FasL expression evaluated by IHC, p<0.001 (Chi-square test; 
C). 
 
Figure legends
Table 1 – Polymorphism genotypes distribution and risk of recurrence after BCG 
therapy. 
OR: Odds ratio 
95%CI: 95% Confidence Interval 
a
: Chi-square test 
 
 Responders Non-
responders 
OR 95%CI P value
a
 
 n (%) n (%)    
FAS-607A/G      
AA 24 (31.2) 16 (33.3) 1.0   
AG+GG 53 (68.8) 32 (66.7) 0.906 0.419-1.952 0.801 
FASL-844T/C      
TT+TC 58 (75.3) 30 (62.5) 1.0   
CC 19 (24.7) 18 (37.5) 1.832 0.839-3.999 0.127 
Table 1
Table 2 – Relation between patients, clinical and tumor characteristics and BCG treatment 
outcome 
a
: Chi-square test; *: 1.6% of them are pure CIS and 8.8% are concomitant CIS. 
 
 
Variables Total Responders Non-
Responders 
P value
a
 
 n (%) n (%) n (%)  
Stage     
Ta 51 (40.8) 32 (41.6) 19 (39.6) 0.827 
T1 74 (59.2) 45 (58.4) 29 (60.4)  
Grade     
Low  26 (22.7) 17 (22.1) 9 (18.8) 0.656 
High 99 (77.3) 60 (77.9) 39 (81.2)  
Size (cm)     
<3 77 (69.4) 47 (69.1) 30 (69.8) 0.942 
≥3 34 (30.6) 21 (30.9) 13 (30.2)  
Tumor number     
Unifocal 59 (47.2) 40 (51.9) 19 (39.6) 0.178 
Multifocal 66 (52.8) 37 (48.1) 29 (60.4)  
CIS     
No 112 (89.6) 67 (87.0) 45 (93.8) 0.230 
Yes 13 (10.4)* 10 (13.0) 3 (6.2)  
Recurrence status     
Primary 65 (52.0) 41 (53.2) 24 (50.0) 0.724 
Recurrent 60 (48.0) 36 (46.8) 24 (50.0)  
Treatment scheme     
iBCG 55 (44.0) 26 (35.1) 41 (58.3) 0.011 
mBCG 70 (56.0) 60 (64.9) 5 (41.7)  
Table 2
Table 3 – Multivariate analysis and risk estimation of FASL-844T/C, treatment scheme and 
tumor number on BCG immunotherapy outcome  
 
 
 
 
 
 
 
 
HR: Hazard ratio 
95%CI: 95% Confidence Interval 
 
 HR 95%CI P value 
FASL-844T/C    
TT+TC 1.0   
CC 1.881
 
1.040-3.402 0.037 
Treatment scheme    
mBCG 1.0   
iBCG 2.363 1.316-4.243 0.004 
Tumor number    
Unifocal 1.0   
Multifocal 2.092 1.150-3.803 0.016 
Table 3
